Healthcare of Ontario Pension Plan Trust Fund Purchases 228,300 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 37.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 843,300 shares of the company's stock after buying an additional 228,300 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned about 1.08% of Travere Therapeutics worth $11,798,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Aigen Investment Management LP bought a new position in shares of Travere Therapeutics in the 3rd quarter valued at approximately $170,000. Assenagon Asset Management S.A. lifted its stake in shares of Travere Therapeutics by 912.5% in the second quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company's stock worth $18,200,000 after buying an additional 1,995,419 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Travere Therapeutics in the third quarter worth $673,000. Acadian Asset Management LLC boosted its holdings in shares of Travere Therapeutics by 202.6% during the 2nd quarter. Acadian Asset Management LLC now owns 144,901 shares of the company's stock worth $1,190,000 after buying an additional 97,020 shares during the period. Finally, Millennium Management LLC grew its stake in Travere Therapeutics by 33.9% in the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company's stock valued at $24,244,000 after buying an additional 747,406 shares during the last quarter.

Travere Therapeutics Trading Up 0.6 %

Shares of NASDAQ:TVTX traded up $0.11 during trading on Friday, hitting $18.81. 1,489,131 shares of the company's stock were exchanged, compared to its average volume of 1,397,140. The firm has a 50-day moving average price of $17.11 and a two-hundred day moving average price of $11.71. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $20.33. The firm has a market cap of $1.47 billion, a P/E ratio of -4.15 and a beta of 0.70. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business's quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.17) EPS. Equities analysts predict that Travere Therapeutics, Inc. will post -3.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright decreased their price target on shares of Travere Therapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a report on Friday, September 27th. Leerink Partners restated an "outperform" rating and set a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Citigroup dropped their price target on Travere Therapeutics from $23.00 to $19.00 and set a "buy" rating on the stock in a research report on Friday, September 27th. Canaccord Genuity Group reduced their price objective on Travere Therapeutics from $23.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, September 30th. Finally, Wells Fargo & Company raised shares of Travere Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.62.

Insider Buying and Selling

In related news, SVP William E. Rote sold 4,387 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the sale, the senior vice president now owns 84,455 shares in the company, valued at $972,921.60. This represents a 4.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Sandra Calvin sold 12,090 shares of Travere Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.30, for a total value of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $1,005,164.10. This represents a 18.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 122,797 shares of company stock valued at $1,725,559 in the last 90 days. 3.75% of the stock is owned by insiders.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.